共 50 条
- [41] A phase I trial of oblimersen and gemcitabine in refractory and advanced malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 234S - 234SFisher, GAdvani, RWakelee, HJacobs, CGladysheva, KFitzgerald, AMSikic, B
- [42] Phase 1 study of bavituximab in advanced solid tumor malignancies: Final resultsCANCER RESEARCH, 2010, 70Ibrahim, NuhadWong, LucasStopeck, AlisonRosen, Lee S.Gerber, David E.Shan, Joseph S.
- [43] Phase I study of lurbinectedin in Japanese patients with pretreated advanced tumours: Final resultsANNALS OF ONCOLOGY, 2020, 31 : S478 - S478Takahashi, S.Shimizu, T.Doi, T.Lopez-Vilarino, J. A.Nunez Martin, R.Kahatt, C.Fernandez Teruel, C.Sasamoto, H.Zeaiter, A.
- [44] Results from phase I study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 217S - 217SKirkpatrick, LDragovich, TRamanathan, RSharlow, EChow, SWilliams, DHimler, RBaker, AEgorin, M
- [45] A Phase I study of indoximod in patients with advanced malignanciesONCOTARGET, 2016, 7 (16) : 22928 - 22938Soliman, Hatem H.Minton, Susan E.Han, Hyo SookIsmail-Khan, RoohiNeuger, AnthonyKhambati, FatemaNoyes, DavidLush, RichardChiappori, Alberto A.Roberts, John D.Link, CharlesVahanian, Nicholas N.Mautino, MarioStreicher, HowardSullivan, Daniel M.Antonia, Scott J.
- [46] Final reporting of a phase I clinical trial of the oral PPAR-gamma against, CS-7017, in patients with advanced malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Pishvalan, M. J.Cotarla, I.Wagner, A. J.Deeken, J. F.He, A. R.Hwang, J. J.Demetri, G. D.Halim, A.Copigneaux, C.Marshall, J.
- [47] ENCEPHALOPATHY IS THE DOSE-LIMITING TOXICITY OF INTRAVENOUS HEPSULFAM - RESULTS OF A PHASE-I TRIAL IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIESCANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 36 (03) : 204 - 210LARSON, RAGELLER, RBJANISCH, LMILTON, JGROCHOW, LBRATAIN, MJ
- [48] Final results of a phase I study of oral belinostat (PXD101) in patients with lymphomaJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Zain, J. M.Foss, F.Kelly, W. K.DeBono, J.Petrylak, D.Narwal, A.Neylon, E.Blumenschein, G.Lassen, U.O'Connor, O. A.
- [49] Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II TrialBLOOD, 2022, 140 : 9091 - 9093Arslan, ShukaibFleming, ShaunJain, NitinMartinelli, GiovanniStein, Anthony S.Blachly, James S.Bajel, AshishCurti, AntonioMarconi, GiovanniFabbri, GiuliaMarmor, YotvatSharma, ShringiElgeioushi, NairouzCouto-Francisco, NataliaSaeh, JamalTibes, RaoulCader, Fathima ZumlaKonopleva, Marina
- [50] Safety and efficacy results from a phase I dose -escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignanciesCANCER RESEARCH, 2016, 76Wainberg, Zev A.Hecht, J. RandolphKonecny, Gottfried E.Goldman, Jonathan W.Sadeghi, SaeedChmielowski, BartoszSingh, ArunFinn, Richard S.Martinez, DiegoYonemoto, LisaGlaspy, JohnSlamon, Dennis J.